https://scholars.lib.ntu.edu.tw/handle/123456789/549444
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Tsai H.-J. | en_US |
dc.contributor.author | Shih N.-Y. | en_US |
dc.contributor.author | SUNG-HSIN KUO | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | Lin H.-Y. | en_US |
dc.contributor.author | Chen T.-Y. | en_US |
dc.contributor.author | Chang K.-C. | en_US |
dc.contributor.author | Lin S.-F. | en_US |
dc.contributor.author | Chang J.S. | en_US |
dc.contributor.author | Chen L.-T. | en_US |
dc.creator | Tsai H.-J.;Shih N.-Y.;Sung-Hsin Kuo;Cheng A.-L.;Lin H.-Y.;Chen T.-Y.;Chang K.-C.;Lin S.-F.;Chang J.S.;Chen L.-T. | - |
dc.date.accessioned | 2021-02-23T08:26:23Z | - |
dc.date.available | 2021-02-23T08:26:23Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1042-8194 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84946052219&doi=10.3109%2f10428194.2014.995647&partnerID=40&md5=8826aead274210da19f43b0ae1725731 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/549444 | - |
dc.description.abstract | Recurrent genetic alterations that are frequently observed in some low-grade lymphomas, such as activated B cell subtype of diffuse large B-cell lymphoma (ABC-DLBCL) and mucosa-associated lymphoid tissue type lymphoma (MALT lymphoma) are usually associated with nuclear factor-B (NF-B) activation and confer resistance to therapy. In this study, we investigated the therapeutic efficacy and molecular mechanisms of AUY922, a novel Hsp90 inhibitor, in representative cell lines OCI-Ly3 (ABC-DLBCL) and MA-1 (a low-grade lymphoma cell line with t(14;18)/IgH-MALT1translocation) to explore its potential use in the treatment of refractory B-cell lymphoma. Our results showed that AUY922 effectively induced growth inhibition and apoptosis of OCI-Ly3 and MA-1 cells, which were accompanied by down-regulation of the expression levels of NF-B and Bcl-2 family proteins, as well as molecules of multiple signaling pathways involving cell proliferation, growth and survival. The growth inhibitory effect of AUY922 was further confirmed in a mouse xenograft model. These findings indicate the potential use of AUY922 in B cell lymphomas. ? 2015 Informa UK, Ltd. | - |
dc.publisher | Taylor and Francis Ltd | - |
dc.relation.ispartof | Leukemia and Lymphoma | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | caspase 3; caspase 9; immunoglobulin enhancer binding protein; luminespib; protein bcl 2; 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide; antineoplastic agent; caspase 3; caspase 9; heat shock protein 90; immunoglobulin enhancer binding protein; isoxazole derivative; resorcinol derivative; activated B cell subtype of diffuse large B cell lymphoma; activated B cell subtype of diffuse large B cell lymphoma; animal experiment; animal model; apoptosis; Article; B lymphocyte; cancer inhibition; cell activation; cell cycle arrest; cell growth; cell proliferation; cell survival; controlled study; down regulation; drug efficacy; enzyme activation; growth inhibition; large cell lymphoma; male; marginal zone lymphoma; mouse; nonhuman; priority journal; protein expression; animal; antagonists and inhibitors; B lymphocyte; cancer grading; cell cycle checkpoint; chromosome 14; chromosome 18; chromosome aberration; disease model; drug effects; drug screening; gene translocation; genetics; human; Lymphoma, Large B-Cell, Diffuse; metabolism; mitochondrion; pathology; signal transduction; tumor cell line; tumor volume; Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromosome Aberrations; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Disease Models, Animal; Down-Regulation; Enzyme Activation; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lymphoma, Large B-Cell, Diffuse; Male; Mice; Mitochondria; Neoplasm Grading; NF-kappa B; Resorcinols; Signal Transduction; Translocation, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | - |
dc.title | AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-B activation | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.3109/10428194.2014.995647 | - |
dc.identifier.pmid | 25535814 | - |
dc.identifier.scopus | 2-s2.0-84946052219 | - |
dc.relation.pages | 2674-2682 | - |
dc.relation.journalvolume | 56 | - |
dc.relation.journalissue | 9 | - |
item.fulltext | no fulltext | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Radiation Oncology-NTUCC | - |
crisitem.author.dept | Division of Radiation Oncology | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0003-0054-887X | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | Oncology-NTUH | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。